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Abstract
Background: Symptoms in polycystic liver disease (PLD) are thought to be caused by compression of organs and structures
by the enlarged liver.
Aim: The aim of this article is to assess the impact of liver volume on symptoms and quality of life (QoL) in PLD.
Methods: We included PLD patients from two prospective studies that used the PLD-questionnaire (PLD-Q) for symptom
assessment. QoL was assessed through SF-36, summarized in a physical (PCS) and mental (MCS) component score. Liver
volume was correlated with PLD-Q total scores. Patients were classified based on height-corrected liver volume in mild
(<1600ml), moderate (1600–3200ml), and severe (>3200ml) disease. PLD-Q and QoL (PCS and MCS) scores were compared
across disease stages.
Results: We included 82 of 131 patients from the original studies (disease stages; mild n¼ 26, moderate n¼ 33, and severe
n¼ 23). Patients with larger liver volume reported higher symptom burden (r¼ 0.516, p< 0.001). Symptom scores increased
with disease progression, except for abdominal pain (p¼ 0.088). PCS decreased with advancing disease (p< 0.001), in
contrast to MCS (p¼ 0.055). Moderate (p¼ 0.007) and severe (p< 0.001) PLD patients had lower PCS scores than the general
population.
Conclusion: PLD with larger liver volume is more likely to be symptomatic and is associated with lower QoL.
Keywords
Autosomal dominant polycystic kidney disease (ADPKD), autosomal dominant polycystic liver disease (ADPLD), hepatomeg-
aly, symptoms, quality of life
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Introduction
Polycystic liver disease (PLD) is characterized by
formation of multiple cysts that causes progressive
liver enlargement.1 It occurs isolated in autosomal
dominant polycystic liver disease (ADPLD) and in
coexistence of kidney cysts in autosomal dominant
polycystic kidney disease (ADPKD).1,2 As liver
function impairment is absent in PLD, the contention
is that PLD-related symptoms are caused by compres-
sion of adjacent organs and structures by the enlarged
cystic liver.
Improving insight into mechanisms underlying the
development of PLD-related symptoms is paramount
to optimize treatment strategies, as indications for ther-
apy in PLD are almost completely driven by symptoms.
Knowledge on symptom patterns and quality of life
(QoL) in diﬀerent disease stages informs patients
about the natural course of the disease.
A recent Korean study reported more abdominal
symptoms in PLD patients with larger liver volumes.
However, it is unknown whether these results can be
translated to a Western population as anthropometric
properties of Asians are diﬀerent and culture can inﬂu-
ence symptom presentation.3,4 Furthermore, this study
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used a general gastrointestinal symptom rating scale
instead of a validated PLD-questionnaire (PLD-Q)5
that lacks PLD-related problems such as fear and anx-
iety about the future, limited mobility, tiredness and
problems with intercourse.6 A complete assessment of
PLD-related symptoms is important to fully compre-
hend the impact of liver volume on PLD. Finally, the
impact of liver volume on QoL in diﬀerent disease
stages remains to be elucidated.
In this analysis we investigated the impact of liver
volume on PLD-related symptoms and QoL in a
Western PLD population using data from two pro-
spective studies that reﬂect diﬀerent PLD disease
stages.
Methods
Study design
We pooled baseline data from two prospective studies
that used the PLD-Q to assess symptoms in PLD: (1)
the Developing Interventions to halt Progression of
ADPKD (DIPAK) Observational Study and (2)
the Controlled trial of URSOdeoxycholic acid to
Reduce liver volume in polycystic liver disease
(CURSOR) study. The DIPAK Observational study
is a multicenter, longitudinal study to investigate
disease progression in ADPKD. We included patients
who were enrolled in Radboud University Nijmegen
Medical Center, Nijmegen, the Netherlands, before
March 2016. CURSOR is an international, multicenter,
randomized, controlled clinical trial that assesses the
eﬃcacy of ursodeoxycholic acid as a volume-reducing
treatment in symptomatic PLD.7 Patients were enrolled
from May 2014 through February 2015 in Radboud
University Nijmegen Medical Center, Nijmegen, the
Netherlands; Academic Medical Center, Amsterdam,
the Netherlands; and the Biodonostia Health
Research Institute, Donostia-San Sebastia´n, Spain.
Original studies were approved by local institutional
review boards and were conducted according to the
ethical guidelines of the 1975 Declaration of Helsinki.
In case a patient participated in both studies, we used
the most recent data.
Patients
Adult PLD patients who completed the PLD-Q and
imaging (computed tomography (CT) in CURSOR
and magnetic resonance imaging (MRI) in DIPAK
patients) at baseline were eligible for this analysis.
PLD was deﬁned as 20 hepatic cysts on MRI or
CT, which was judged independently by two investiga-
tors (MN and SV). Patients were categorized by a
previously published disease classiﬁcation for PLD.5
Mild disease was deﬁned as <1600ml height-corrected
liver volume (htLV), moderate as 1600–3200ml and
>3200ml as severe disease. We excluded patients with
abdominal surgery six months prior to baseline and
patients with more than one month between scan and
PLD-Q to limit bias in the relation between symptoms
and liver volume.
PLD-Q
Patients completed the PLD-Q (version 1) to assess
frequency and discomfort of PLD-associated symp-
toms.6 The PLD-Q is an extensively validated
patient-reported outcome measure including 13 dis-
ease-speciﬁc symptoms. Each individual symptom is
assessed with a frequency (six-point Likert scale
‘‘never’’ to ‘‘always’’) and discomfort (ﬁve-point
Likert scale ‘‘not at all’’ to ‘‘a lot’’) question.
Severity scores of individual symptoms are the sum
of the frequency and discomfort score (range 2–11).
A severity score of 2–3 can be considered as no
symptoms, 4–5 as mild, 6–7 as moderate, 8–9 as
moderately severe and 10–11 as severe symptoms.
The PLD-Q total score is the sum of all severity
scores and was transformed to a score of 0–100,
where a higher score represents a higher symptom
burden. Total scores were missing when 2 severity
scores were missing.
QoL
QoL was assessed with the Short-Form 36 (SF-36), a
generic questionnaire that contains 36 questions that
can be summarized in a physical (PCS) and mental
(MCS) component scale.8 The scores of the PCS and
MCS range from 8 to 73 and 10 to 74, respectively,
whereas lower scores represent a lower QoL. Scores
and missing data of the SF-36 were handled according
to the user’s manual.9
Liver volumes
Liver and kidney volumes were measured with a seg-
mentation technique, which involves manual tracing
of the liver boundaries. A software program interpol-
ates between CT or MRI slices and calculates the
areas within the indicated circumference. For liver
segmentation we included liver parenchyma and
cysts, the gallbladder, vessels surrounded by liver par-
enchyma and vessels that are part of the liver hilum.
Kidney segmentation included kidney tissue, kidney
cysts, pyelum and main kidney vessels when fully
surrounded by kidney tissue. Excluded were pyelum
and kidney vessels when not surrounded by kidney
tissue.
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For CT scans we used Pinnacle3 volumetric soft-
ware version 9.10 (Philips Radiation Oncology
Systems; Fitchburg, WI, USA), which has been vali-
dated previously for PLD.10–12 MRI scans were mea-
sured with ITK-SNAP version 3.4.0 (Penn Image
Computing and Science Laboratory, Philadelphia,
PA, USA, and Scientiﬁc Computing and Imaging
Institute, Salt Lake City, UT, USA). We validated
ITK-SNAP to measure liver volumes in PLD for
this study (Supplemental Appendix) and found a
mean diﬀerence in liver volume of 1.8% 1.1
between ITK-SNAP measurements and Pinnacle3.
Variability between ITK-SNAP measurements by
two independent investigators was 0.4% 1.4.
These diﬀerences were considered acceptable for the
purpose of our study.
Excluded:
Excluded:
DIPAK
n=51 n=32
CURSOR studyobservational
Total included patients
(n=82)
study
(n=97)
26
6
6
1
7
0
1
0
0
1
(n=34)
No polycystic liver (n=26)
Included in both studies (n=1)
No PLD-Q availble (n=7)
No imaging availble (n=8)
Abdominal surgery < 6 months (n=1)
Time scan and PLD-Q > 1 month (n=6)
Figure 1. Flowchart shows reasons for exclusion from original studies. Of the 131 patients assessed for eligibility, 82 were included in the study.
PLD-Q: polycystic liver disease questionnaire; DIPAK: Developing Interventions to halt Progression of autosomal dominant polycystic
kidney disease (ADPKD); CURSOR: Controlled trial of URSOdeoxycholic acid to Reduce liver volume in polycystic liver disease
Table 1. Characteristics of included patients categorized by disease stage.
Mild< 1600ml
(n¼ 26)
Moderate 1600–3200ml
(n¼ 33)
Severe >3200ml
(n¼ 23) p value
Age, median (IQR), years 48 (33–57) 49 (46–57) 43 (40–56) 0.232b
Female, n (%) 18 (69) 28(85) 21 (91) 0. 114c
Diagnosis ADPKD, n (%) 24 (92) 24 (73) 17 (52) 0.139c
HtLV (ml/m), median (IQR) 1087 (924–1306) 2375 (1941–2754) 4571 (3868–5411) 0.002b
HtKV (ml/m), median (IQR)a 801 (374–1191) 836 (361–1275) 614 (380–1480) 0.258b
Renal function (eGFR), median (IQR)a 73 (44–86) 64 (46–77) 71 (54–84) 0.177b
aKidney volumes and renal function of ADPKD patients only. P values tested with bKruskal-Wallis test or cChi-Square test. eGFR: estimated glomerular
filtration rate using the Modification of Diet in Renal Disease formula; ADPKD: autosomal dominant polycystic kidney disease; htKV: height-corrected kidney
volume; htLV: height-corrected liver volume; IQR: interquartile range.
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Statistical analysis
Patient characteristics are presented across disease
stages as median with interquartile range (IQR) or as
proportion of total and compared with the Kruskal-
Wallis test or chi-squared test. Liver (htLV) and
kidney (htKV) volumes were height-corrected and
log-transformed to get normally distributed variables
for further analysis. Correlation between htLV and
PLD-Q total score was calculated with Spearman’s cor-
relation coeﬃcient. As the CURSOR study included
symptomatic patients with larger liver volumes, we per-
formed a sensitivity analysis in DIPAK patients to
assess whether selection bias has confounded this cor-
relation. Subsequently, we assessed whether the relation
between htLV and symptoms remained signiﬁcant after
adjustment for possible confounders with a multivari-
ate analysis. We entered the PLD-Q total score as an
independent variable and htLV, age, gender, diagnosis
and original study (CURSOR or DIPAK) as dependent
variables. In the subgroup of ADPKD patients, we also
entered htKV and renal function (estimated glomerular
ﬁltration rate using the Modiﬁcation of Diet in Renal
Disease) in the multivariate model.
To assess whether individual symptoms and QoL
(PCS and MCS) were distributed diﬀerently across dis-
ease stages, scores were compared with the Kruskal-
Wallis test. A one-sample Wilcoxon rank test was per-
formed to determine whether QoL scores (PCS and
MCS) were diﬀerent from general population
norm scores. As PLD occurs predominantly in females,
we used female reference norm scores (51.03
(41.10–55.86) and MCS: 52.80 (43.40–57.19)).9
Signiﬁcant diﬀerences were compared with age-
matched female reference values to assess whether the
diﬀerence holds true.9 Statistical analyses were per-
formed in SPSS version 22.0 (IBM Corp., Armonk,
NY, USA). The signiﬁcance level was set to a p
value< 0.05.
Results
Patient characteristics
From the 131 patients included in the original studies,
82 patients were eligible for this study. Figure 1 depicts
reasons for exclusion. Table 1 shows patient character-
istics categorized by disease stage. We included 26 mild
PLD patients, 33 patients with moderate disease, and
23 patients with severe PLD. Median age, gender, and
underlying diagnosis (ADPKD or ADPLD) were not
signiﬁcantly diﬀerent across the disease stages. In the
ADPKD subgroup as well, no diﬀerences between renal
function and kidney volume were found.
Symptom distribution
PLD-Q total score could be calculated in all patients.
Figure 2 shows the distribution of symptoms in the
total study population. The majority had at least mild
symptoms of tiredness (81.7%), fullness (78.0%), dis-
satisfaction with abdomen size (72.8%) and limited
mobility (72%). Only 36.6% experienced lack of appe-
tite (mild or higher severity). The most burdensome
symptom, scored as moderately severe or severe was
dissatisfaction with abdomen size (40.8%), followed
by pain and pressure in the rib cage (32.1%), tiredness
Lack of appetite % No symptoms (2-3)
Mild symptoms (4-5)
Moderate symptoms (6-7)
Moderately-severe symptoms (8-9)
Severe symptoms (10-11)
Problems with intercourse %
Fear/anxiety future %
Abdominal pain %
Early satiety %
Pain or pressure rib cage %
Pain in side %
Shortness of breath %
Limited mobility %
Dissatisfaction abdomen size %
Fullness %
Tiredness %
0 20 40 60 80 100
Nausea %
Figure 2. Severity of individual symptoms (%) as scored on the polycystic liver disease questionnaire (PLD-Q) in the total study
population. Scores are ranging from 2 to 11, whereas higher scores correspond with more severe symptoms (darker bars).
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(29.2%), fullness (28.0%) and limited mobility (26.8%).
None of the patients experienced severe nausea or
abdominal pain.
Correlation symptoms and htLV
Patients with larger htLV reported higher symptom
burden measured with the PLD-Q (r¼ 0.532,
p< 0.001). Sensitivity analysis in DIPAK patients
showed also a signiﬁcant correlation (r¼ 0.621,
p< 0.001). In the multivariate model, the association
between symptoms measured with the PLD-Q and
htLV remained signiﬁcant (p< 0.001) after adjustment
for age (p¼ 0.50), gender (p¼ 0.02), diagnosis (p¼ 0.05)
and the original study (p¼ 0.19) (Table 2). In the
ADPKD subgroup, symptom burden was still asso-
ciated with htLV (p< 0.001) after adjustment for age
(p¼ 0.69), gender (p¼ 0.02), original study (p¼ 0.24),
htKV (p¼ 0.27) and renal function (p¼ 0.46).
Severity of individual symptoms across disease
stages
Figure 3 shows the median individual symptom scores
per disease stage. All individual symptom scores were
higher at more advanced disease stages, except for
abdominal pain (p¼ 0.088). In mild PLD, only one
symptom of a mild nature was present (tiredness). In
moderate PLD, patients had ﬁve symptoms of at least
moderate severity and this increased to seven symptoms
of this nature in severe PLD. The most burdensome
symptom with a moderately severe nature was dissatis-
faction with abdomen size in moderate and severe
stages.
Quality of life across disease stages
SF-36 data were available in 79 patients (mild n¼ 24;
moderate n¼ 32; and severe disease n¼ 23). The PCS
decreased signiﬁcantly with advancing disease stage
(p¼ 0.021), while there was no signiﬁcant eﬀect of dis-
ease stage on the MCS (p¼ 0.055) (Figure 4). PCS of
mild PLD patients was similar to the female reference
population (53.30 (42.47–55.86) vs. 51.03, p¼ 0.932).
The PCS of moderate (46.15 (32.16–53.81) vs. 51.03,
p¼ 0.007) and severe (44.09 (38.93–46.94) vs. 51.03,
p< 0.001) PLD patients was signiﬁcantly lower com-
pared to the female reference population. This diﬀerence
remained after comparing with an age-matched refer-
ence population (PCS 51.61, p¼ 0.004 and p< 0.001).
Discussion
We show that PLD patients with more severe hepato-
megaly have a higher symptom burden, with increasingTa
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symptom severity across all components of the PLD-Q,
except for abdominal pain. QoL, particularly the phys-
ical component, decreases with advancing disease and
drops below levels seen in the general population in
patients with htLV 1600ml.
Liver volume aﬀected symptom burden and QoL in
those with moderate disease stage and beyond, suggest-
ing that liver volume-reducing therapies are beneﬁcial
in these patients. As patients with htLV> 1600ml also
have a higher risk of pressure-related complications
compared to patients with smaller livers,5 this liver
volume can be used as evidence-based inclusion criteria
for symptomatic disease in future studies.
There were no large diﬀerences in symptom patterns
per disease stage between the Western and Asian popu-
lation,5 indicating that possible diﬀerences in culture
and anthropometric properties have no large eﬀect on
symptom development in PLD.
Surprisingly, abdominal pain was not associated
with disease stage. Although frequency of abdominal
pain seems to be increased in PLD compared to the
general population,6,13 we found no correlation with
liver volume. This accords with another large study in
1043 ADPKD patients that also did not establish a
relation between abdominal pain and liver or kidney
volume.14 It is possible that cyst growth rather than
2
3
4
5
6
7
8
9
10
11
Fullness p <0.001** 
Lack of appetite p =0.029* 
Early satiety p <0.001** 
Nausea p =0.046*  
Pain/pressure rib 
cage p <0.001**       
Pain in side p =0.018* 
Abdominal pain p =0.088 Shortness of breath p =0.011* 
Limited mobility p =0.001* 
Tiredness p =0.029* 
Fear/anxiety future p <0.001** 
Dissatisfaction abdomen 
size p <0.001** 
Problems with 
intercourse p <0.001** 
Mild PLD (htLV <1600 mL)
Moderate PLD (htLV 1600-3200 mL)
Severe PLD (htLV >3200 mL)
Figure 3. Median individual symptom scores per disease stage. A severity score of 2-3 can be considered as no symptoms (center), 4-5 as
mild, 6-7 as moderate, 8-9, as moderately-severe, and 10-11 as severe symptoms (most outer lines).
PLD: polycystic liver disease; htLV: height-corrected liver volume.
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Figure 4. Left panel: physical component scores (PCS) decreased significantly with advancing disease stages (p = 0.021). Right panel: no
significant effect of disease stage on the mental component scale (MCS) (p = 0.055). The dotted line reflects the reference value of the
general population. Disease stages are defined as: mild <1600 mL, moderate 1600–3200 mL; and severe >3200 mL height corrected liver
volume.
PLD: polycystic liver disease; SF-36: Short-Form 36.
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mere static liver volume is responsible for symptoms of
abdominal pain.
The main strength of this study is that we were able
to include the whole spectrum of liver volumes from
rather normal volumes (htLV 834ml) to very severe
hepatomegaly with htLVs up to 10 times as large
(htLV 8382ml). Our cohort was highly enriched with
severe PLD because inclusion mainly took place at a
national referral center. In comparison, the prevalence
of this stage in the general ADPKD population is
approximately 5%, leading to similar numbers of
patients with severe PLD in our study compared to
large studies that include more than 450 patients.5,15
This enrichment enabled us to compare symptoms
and QoL across diﬀerent disease stages.
We used a reliable and extensively validated disease-
speciﬁc questionnaire to assess symptom burden in
PLD.6 This instrument allowed us to investigate the
broad spectrum of symptoms in PLD, while generic
gastrointestinal questionnaires under-represent some
problems related to PLD.
Limitation of the cross-sectional design is that we
could not assess the eﬀect of liver volume growth on
symptoms. Although the CURSOR trial has a longitu-
dinal design, mean increase in liver volumes was only
4%, which is too small to conclude whether change in
liver volume led to aggravation of symptoms.7 This
longitudinal relationship should be a topic for future
studies, for instance, when follow-up data of the
DIPAK study become available.
Second, the CURSOR included symptomatic
patients with (uncorrected) liver volumes> 2500ml,
while the DIPAK inclusion criteria are independent of
symptoms and liver volume. The enrichment of symp-
tomatic patients with larger livers may result in a spuri-
ous correlation between symptoms and liver volume.
However, the fact that correlation between symptoms
and liver volume was even stronger in the sensitivity
analysis restricted to DIPAK-enrolled patients fuels
the contention that this correlation is independent of
inclusion criteria.
Finally, we pooled two studies with diﬀerent ima-
ging modalities. To validate pooling of MRI and CT
images in our study, we compared the two diﬀerent
volumetric software packages and diﬀerences were
small (1.8%). In addition, a randomized controlled
trial that assesses changes in liver volume after somato-
statin analog treatment also found excellent correlation
between liver volumes measured from CT and MRI
images.16 Therefore, we think that this has not inﬂu-
enced our results.
This study suggests that an alternative diagnosis
than merely PLD should be considered in patients
with mild PLD presenting with moderate to severe
symptoms. In case of ADPKD, symptoms might be
related to large polycystic kidneys rather than liver
when PLD stage does not correlate with the experi-
enced symptoms. Given that tiredness and dissatisfac-
tion with abdomen size were respectively the most
frequent and burdensome symptoms, clinicians should
support adequate coping strategies to reduce this
burden. We suggest that abdominal pain should not
be the primary indication to start therapy, since no
study so far has detected a relation with static liver
volume or cyst growth.
In conclusion, larger liver volume has a negative
impact on symptoms and QoL in PLD. Particularly,
polycystic livers above twice the normal size
(1600ml htLV) are associated with symptomatic dis-
ease and QoL impairment. We suggest this volume as
evidence-based inclusion criteria for future studies
investigating new therapies for symptomatic PLD.
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